COMPREHENSIVE CROSS-DATABASE IDENTIFIER AND FUNCTIONAL MAPPING REFERENCE
Human MYC (c-Myc Proto-Oncogene)
Section 1: Gene Identifiers
Primary Gene Identifiers
| Database | Identifier | Notes |
|---|
| HGNC ID | HGNC:7553 | Approved |
| HGNC Symbol | MYC | Approved symbol |
| Full Name | MYC proto-oncogene, bHLH transcription factor | |
| Ensembl Gene | ENSG00000136997 | GRCh38 |
| NCBI Entrez Gene | 4609 | protein-coding |
| OMIM | 190080 | Gene/Locus |
| Locus Type | gene with protein product | |
| Locus Group | protein-coding gene | |
| Status | Approved | |
Genomic Location (GRCh38/hg38)
| Attribute | Value |
|---|
| Chromosome | 8 |
| Cytogenetic Band | 8q24.21 |
| Start Position | 127,735,434 |
| End Position | 127,742,951 |
| Strand | + (forward) |
| Gene Length | 7,518 bp |
| Biotype | protein_coding |
Gene Aliases & Previous Names
| - Aliases | - Previous Name | - Gene Group | Ensembl Transcripts (Total |
|---|
| c-Myc, bHLHe39, MYCC | v-myc avian myelocytomatosis viral oncogene homolog | Basic helix-loop-helix proteins | | |
| | | Transcript Identifiers** | 15) |
| Transcript ID | Biotype | Start | End | Strand |
|---|
| ENST00000259523 | protein_coding | 127,735,434 | 127,740,477 | + |
| ENST00000377970 | protein_coding | 127,736,084 | 127,741,434 | + |
| ENST00000517291 | protein_coding | 127,735,519 | 127,738,772 | + |
| ENST00000520751 | protein_coding_CDS_not_defined | 127,736,231 | 127,738,475 | + |
| ENST00000524013 | protein_coding | 127,736,220 | 127,741,372 | + |
| ENST00000621592 | protein_coding | 127,736,231 | 127,742,951 | + |
| ENST00000641036 | protein_coding | 127,736,046 | 127,736,612 | + |
| ENST00000641252 | protein_coding | 127,735,473 | 127,735,817 | + |
| ENST00000651626 | protein_coding | 127,735,659 | 127,741,434 | + |
| ENST00000652288 | protein_coding | 127,737,621 | 127,741,434 | + |
| ENST00000707113 | protein_coding | 127,736,958 | 127,741,434 | + |
| ENST00000707114 | protein_coding | 127,737,724 | 127,741,434 | + |
| ENST00000707115 | protein_coding | 127,737,737 | 127,741,434 | + |
| ENST00000707116 | protein_coding | 127,737,745 | 127,741,434 | + |
| ENST00000707117 | protein_coding_CDS_not_defined | 127,739,073 | 127,741,434 | + |
RefSeq Transcripts (Human)
| Accession | Type | Chromosome | Status | MANE Select |
|---|
| NM_002467 | mRNA | 8 | REVIEWED | Yes (Canonical) |
| NM_001354870 | mRNA | 8 | REVIEWED | No |
RefSeq Proteins (Human)
| Accession | Chromosome | Status | MANE Select |
|---|
| NP_002458 | 8 | REVIEWED | Yes (Canonical) |
| NP_001341799 | 8 | REVIEWED | No |
CCDS Identifiers (Total: 2)
Canonical Transcript Exons (ENST00000259523 - 3 exons)
| Exon ID | Start | End | Length | Strand |
|---|
| ENSE00001848036 | 127,735,434 | 127,736,623 | 1,190 bp | + |
| ENSE00003540079 | 127,738,248 | 127,739,019 | 772 bp | + |
| ENSE00001766895 | 127,740,398 | 127,740,477 | 80 bp | + |
| Total Exon Count (canonical) | UniProt Accessions (Total |
|---|
| 3 | | |
| Protein Identifiers** | 6) |
| Accession | Name | Status | Length | Mass |
|---|
| P01106 | Myc proto-oncogene protein | Reviewed (Canonical) | 454 aa | 50,565 Da |
| Q14899 | | Unreviewed | - | - |
| Q16591 | | Unreviewed | - | - |
| A0A0B4J1R1 | | Unreviewed | - | - |
| A0A494C1T8 | | Unreviewed | - | - |
| H0YBG3 | | Unreviewed | - | - |
Canonical Protein Details (P01106)
| Attribute | Value |
|---|
| Primary Name | Myc proto-oncogene protein |
| Alternative Names | Class E basic helix-loop-helix protein 39; Proto-oncogene c-Myc; Transcription factor p64 |
| Length | 454 amino acids |
| Molecular Mass | 50,565 Da |
Protein Domains and Families (InterPro)
| InterPro ID | Name | Type |
|---|
| IPR002418 | Tscrpt_reg_Myc | Family |
| IPR003327 | Myc-LZ | Domain |
| IPR011598 | bHLH_dom | Domain |
| IPR012682 | Tscrpt_reg_Myc_N | Domain |
| IPR036638 | HLH_DNA-bd_sf | Homologous_superfamily |
| IPR050433 | Myc_transcription_factors | Family |
Pfam Domains (Total: 3)
| Pfam ID | Description |
|---|
| PF00010 | Helix-loop-helix DNA-binding domain |
| PF01056 | Myc amino-terminal region |
| PF02344 | Myc-type, basic helix-loop-helix leucine zipper |
Section 4: Structure Identifiers
Experimental Structures (PDB) - Total: 25
| PDB ID | Title | Method | Resolution |
|---|
| 6G6K | Human MYC:MAX bHLHZip complex | X-RAY DIFFRACTION | 1.35 Å |
| 1NKP | Myc-Max recognizing DNA | X-RAY DIFFRACTION | 1.8 Å |
| 4Y7R | WDR5 with MYC MbIIIb peptide | X-RAY DIFFRACTION | 1.898 Å |
| 8Q1N | Cyclic peptide binder of WDR5 | X-RAY DIFFRACTION | 1.843 Å |
| 8J2Q | Cypovirus Polyhedra with c-Myc | X-RAY DIFFRACTION | 1.92 Å |
| 5I4Z | Apo OmoMYC | X-RAY DIFFRACTION | 1.95 Å |
| 8X8V | Cypovirus Polyhedra with c-Myc | X-RAY DIFFRACTION | 2.0 Å |
| 8X8S | Cypovirus Polyhedra with c-Myc | X-RAY DIFFRACTION | 2.04 Å |
| 1EE4 | Karyopherin with c-Myc NLS | X-RAY DIFFRACTION | 2.1 Å |
| 6G6L | Human MYC:MAX bHLHZip complex | X-RAY DIFFRACTION | 2.2 Å |
| 6G6J | Human MYC:MAX bHLHZip complex | X-RAY DIFFRACTION | 2.25 Å |
| 6E16 | c-Myc-TBP-TAF1 ternary | X-RAY DIFFRACTION | 2.4 Å |
| 7T1Y | Fbw7-Skp1-MycCdegron | X-RAY DIFFRACTION | 2.55 Å |
| 8WLG | Cypovirus with c-Myc fragment | X-RAY DIFFRACTION | 2.55 Å |
| 6C4U | FHA with Myc-pTBD peptide | X-RAY DIFFRACTION | 2.6 Å |
| 5I50 | OmoMYC bound to DNA | X-RAY DIFFRACTION | 2.701 Å |
| 2OR9 | Anti-c-myc antibody 9E10 Fab | X-RAY DIFFRACTION | 2.7 Å |
| 7T1Z | Fbw7-Skp1-MycNdegron | X-RAY DIFFRACTION | 2.77 Å |
| 6E24 | c-Myc-TBP-TAF1 ternary | X-RAY DIFFRACTION | 3.001 Å |
| 9QNH | Myc pS294 with 14-3-3sigma | X-RAY DIFFRACTION | 1.3 Å |
| 1A93 | c-MYC-MAX leucine zipper | SOLUTION NMR | - |
| 2A93 | c-MYC-MAX leucine zipper (40 structures) | SOLUTION NMR | - |
| 1MV0 | BIN1 interaction with c-Myc | SOLUTION NMR | - |
| 8OTS | OCT4 and MYC-MAX on nucleosome | ELECTRON MICROSCOPY | 3.3 Å |
| 8OTT | MYC-MAX on nucleosome at SHL+5.8 | ELECTRON MICROSCOPY | 3.3 Å |
Structure Summary:
- X-ray crystallography: 20 structures
- Solution NMR: 3 structures
- Cryo-EM: 2 structures
Predicted Structure (AlphaFold)
| Attribute | Value |
|---|
| AlphaFold ID | P01106 |
| Sequence Length | 3,551 (full entry) |
| Global pLDDT | 61.38 |
| Fraction pLDDT Very High | 0.21 (21%) |
| Note |
|---|
| Low overall confidence reflects intrinsically disordered regions characteristic of transcription factors. | |
| Cross-Species Orthologs** |
Vertebrate Orthologs
| Organism | Gene ID | Symbol | Biotype |
|---|
| Mouse (Mus musculus) | ENSMUSG00000022346 | Myc | protein_coding |
| Rat (Rattus norvegicus) | ENSRNOG00000004500 | Myc | protein_coding |
| Zebrafish (Danio rerio) | ENSDARG00000007241 | mycb | protein_coding |
| Zebrafish (Danio rerio) | ENSDARG00000045695 | myca | protein_coding |
Invertebrate Orthologs
| Organism | Gene ID | Symbol |
|---|
| Fruit fly (D. melanogaster) | FBGN0262656 | Myc |
Orthologs Not Found in Database
| - Worm (C. elegans) | - Yeast (S. cerevisiae) | ClinVar Variants Summary (Total |
|---|
| No direct ortholog | No direct ortholog | | |
| | Clinical Variants & AI Predictions** | 46) |
| Classification | Count |
|---|
| Pathogenic | 4 |
| Likely Pathogenic | 1 |
| Benign | 4 |
| Likely Benign | 3 |
| Benign/Likely Benign | 2 |
| Uncertain Significance (VUS) | 10 |
| Other/Not Classified | 22 |
Pathogenic/Likely Pathogenic Variants
| ClinVar ID | HGVS | Type | Classification |
|---|
| 12574 | NM_002467.6:c.214C>T (p.Pro72Ser) | SNV | Pathogenic |
| 12575 | NM_002467.6:c.302A>C (p.Asn101Thr) | SNV | Pathogenic |
| 12576 | NM_002467.6:c.162G>C (p.Glu54Asp) | SNV | Pathogenic |
| 2658815 | NM_002467.6:c.217A>G (p.Thr73Ala) | SNV | Pathogenic |
| 810340 | 8q24.21 (128750494-128753204)x3 | CNV gain | Likely Pathogenic |
Variants of Uncertain Significance (VUS)
| ClinVar ID | HGVS | Type |
|---|
| 1679939 | c.77A>G (p.Asn26Ser) | SNV |
| 2286886 | c.409G>C (p.Glu137Gln) | SNV |
| 2468497 | c.909C>G (p.Ser303Arg) | SNV |
| 2510151 | c.671C>T (p.Ala224Val) | SNV |
| 2658812 | c.30+4A>T | SNV |
| 3154445 | c.1228A>G (p.Ile410Val) | SNV |
| 3154448 | c.1297G>C (p.Asp433His) | SNV |
| 3297249 | c.544G>A (p.Gly182Ser) | SNV |
| 3400454 | c.814G>A (p.Glu272Lys) | SNV |
| 3915251 | c.688G>T (p.Ala230Ser) | SNV |
SpliceAI Predictions (Total: 522)
Top 20 Predicted Splice-Altering Variants (by delta score)
| Variant ID | Effect | Score |
|---|
| 8:127736625:T:G | donor_loss | 0.98 |
| 8:127736622:AGGT:A | donor_loss | 0.98 |
| 8:127736623:GGT:G | donor_loss | 0.98 |
| 8:127736624:GTAA:G | donor_loss | 0.98 |
| 8:127736610:T:TA | donor_gain | 0.97 |
| 8:127736611:A:AA | donor_gain | 0.97 |
| 8:127736620:CCAG:C | donor_gain | 0.97 |
| 8:127736624:G:GG | donor_gain | 0.96 |
| 8:127736197:C:G | donor_gain | 0.93 |
| 8:127736619:ACCAG:A | donor_gain | 0.93 |
| 8:127737196:G:GT | donor_gain | 0.92 |
| 8:127736621:CAG:C | donor_gain | 0.87 |
| 8:127736612:G:GG | donor_gain | 0.85 |
| 8:127736622:AG:A | donor_gain | 0.82 |
| 8:127736623:GG:G | donor_gain | 0.82 |
| 8:127736196:GC:G | donor_gain | 0.77 |
| 8:127736633:G:GT | donor_gain | 0.75 |
| 8:127737196:GAA:G | donor_gain | 0.73 |
| 8:127736197:C:CG | donor_gain | 0.70 |
| 8:127737198:A:G | donor_gain | 0.68 |
AlphaMissense Predictions (Total: 2,886)
Classification Distribution (sample of first 100)
- Likely benign: ~70%
- Ambiguous: ~20%
- Likely pathogenic: ~10%
Top 20 Predicted Pathogenic Missense Variants
| Variant ID | Protein Change | Pathogenicity Score | Class |
|---|
| 8:127738305:G:C | D15H | 0.739 | likely_pathogenic |
| 8:127738299:G:C | D13H | 0.664 | likely_pathogenic |
| 8:127738300:A:T | D13V | 0.650 | likely_pathogenic |
| 8:127738306:A:T | D15V | 0.650 | likely_pathogenic |
| 8:127738300:A:C | D13A | 0.572 | likely_pathogenic |
| 8:127738305:G:T | D15Y | 0.610 | likely_pathogenic |
Section 7: Biological Pathways & Gene Ontology
Reactome Pathways (Total: 19)
| Pathway ID | Name | Disease? |
|---|
| R-HSA-1362277 | Transcription of E2F targets under negative control by DREAM complex | No |
| R-HSA-201556 | Signaling by ALK | No |
| R-HSA-2122947 | NOTCH1 Intracellular Domain Regulates Transcription | No |
| R-HSA-2173796 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | No |
| R-HSA-2644606 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | Yes |
| R-HSA-2894862 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | Yes |
| R-HSA-4411364 | Binding of TCF/LEF:CTNNB1 to target gene promoters | No |
| R-HSA-5687128 | MAPK6/MAPK4 signaling | No |
| R-HSA-5689880 | Ub-specific processing proteases | No |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | No |
| R-HSA-69202 | Cyclin E associated events during G1/S transition | No |
| R-HSA-69656 | Cyclin A:Cdk2-associated events at S phase entry | No |
| R-HSA-8866911 | TFAP2 family regulates transcription of cell cycle factors | No |
| R-HSA-8951430 | RUNX3 regulates WNT signaling | No |
| R-HSA-9018519 | Estrogen-dependent gene expression | No |
| R-HSA-9616222 | Transcriptional regulation of granulopoiesis | No |
| R-HSA-9764562 | Regulation of CDH1 mRNA translation by microRNAs | No |
| R-HSA-9818749 | Regulation of NFE2L2 gene expression | No |
| R-HSA-9909649 | Regulation of PD-L1(CD274) transcription | No |
Gene Ontology Annotations (Total: 85)
Molecular Function (20 terms)
| GO ID | Term |
|---|
| GO:0000978 | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| GO:0000981 | DNA-binding transcription factor activity, RNA polymerase II-specific |
| GO:0001046 | core promoter sequence-specific DNA binding |
| GO:0001221 | transcription coregulator binding |
| GO:0001227 | DNA-binding transcription repressor activity, RNA polymerase II-specific |
| GO:0001228 | DNA-binding transcription activator activity, RNA polymerase II-specific |
| GO:0003677 | DNA binding |
| GO:0031625 | ubiquitin protein ligase binding |
| GO:0042802 | identical protein binding |
| GO:0044877 | protein-containing complex binding |
| GO:0046983 | protein dimerization activity |
| GO:0070888 | E-box binding |
| GO:0140297 | DNA-binding transcription factor binding |
| GO:0140537 | transcription regulator activator activity |
| GO:1905761 | SCF ubiquitin ligase complex binding |
Biological Process (Top 20 of 53 terms)
| GO ID | Term |
|---|
| GO:0000082 | G1/S transition of mitotic cell cycle |
| GO:0000122 | negative regulation of transcription by RNA polymerase II |
| GO:0000165 | MAPK cascade |
| GO:0006338 | chromatin remodeling |
| GO:0006357 | regulation of transcription by RNA polymerase II |
| GO:0006366 | transcription by RNA polymerase II |
| GO:0006974 | DNA damage response |
| GO:0008284 | positive regulation of cell population proliferation |
| GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage |
| GO:0010468 | regulation of gene expression |
| GO:0010628 | positive regulation of gene expression |
| GO:0016055 | Wnt signaling pathway |
| GO:0016072 | rRNA metabolic process |
| GO:0032204 | regulation of telomere maintenance |
| GO:0043066 | negative regulation of apoptotic process |
| GO:0045893 | positive regulation of DNA-templated transcription |
| GO:0045944 | positive regulation of transcription by RNA polymerase II |
| GO:0051276 | chromosome organization |
| GO:0071456 | cellular response to hypoxia |
| GO:1902255 | positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator |
Cellular Component (12 terms)
| GO ID | Term |
|---|
| GO:0000785 | chromatin |
| GO:0000791 | euchromatin |
| GO:0005634 | nucleus |
| GO:0005654 | nucleoplasm |
| GO:0005730 | nucleolus |
| GO:0005819 | spindle |
| GO:0016604 | nuclear body |
| GO:0030424 | axon |
| GO:0032991 | protein-containing complex |
| GO:0048471 | perinuclear region of cytoplasm |
| GO:0071943 | Myc-Max complex |
| GO:0090571 | RNA polymerase II transcription repressor complex |
Section 8: Protein Interactions & Molecular Networks
STRING Protein-Protein Interactions
- Total Interactions: 14,230+
- Highest Confidence Interactions (score ≥ 900):
| UniProt B | Score | Protein Name |
|---|
| P01106 | 997 | MYC (self) |
| P04637 | 997 | TP53 |
| P38398 | 995 | BRCA1 |
| Q09472 | 994 | EP300 |
| Q9Y4A5 | 993 | TRRAP |
| Q96GN5 | 991 | USP28 |
| Q01094 | 990 | E2F1 |
| O00499 | 989 | BIN1 |
| P25912 | 987 | HIC1 |
| Q9UL40 | 986 | ZNF131 |
| P84022 | 983 | SMAD3 |
| Q9Y6K1 | 983 | DNMT3A |
| Q16665 | 982 | HIF1A |
| Q9NZI8 | 980 | IGF2BP1 |
| Q13105 | 976 | ZBTB17 |
BioGRID Interactions
- Total Interactions: 5,810+
- Experimental Methods: Affinity Capture-MS, Affinity Capture-Western, Two-hybrid, Reconstituted Complex, Biochemical Activity, Synthetic Lethality
Top Interactors (by evidence)
| Gene Symbol | Interaction Types |
|---|
| MAX | Affinity Capture-Western, Affinity Capture-MS |
| FBXW7 | Affinity Capture-Western |
| USP28 | Affinity Capture-Western |
| USP37 | Affinity Capture-Western |
| USP36 | Affinity Capture-Western |
| CREBBP | Affinity Capture-Western, Reconstituted Complex |
| KAT2A | Affinity Capture-Western, Reconstituted Complex |
| TRRAP | Reconstituted Complex |
| SKP2 | Affinity Capture-Western |
| HDAC1 | Affinity Capture-MS |
Protein Structural Similarity (ESM2)
- Total Similar Proteins: 63
- Top 20 by Similarity Score:
| UniProt | Top Similarity | Avg Similarity |
|---|
| P01106 | 1.0000 | 0.9947 |
| P23583 | 1.0000 | 0.9947 |
| P68271 | 1.0000 | 0.9944 |
| P68272 | 1.0000 | 0.9944 |
| P0C0N8 | 1.0000 | 0.9921 |
| P0C0N9 | 1.0000 | 0.9921 |
| A1YG22 | 0.9999 | 0.9947 |
| A2T7L5 | 0.9999 | 0.9948 |
| B8XIA5 | 0.9999 | 0.9948 |
| P01108 | 0.9999 | 0.9942 |
Protein Sequence Similarity (DIAMOND)
- Total Homologs: 65
- Top 20 by Identity:
| UniProt | Identity % | Bitscore | Description |
|---|
| P61244 | 100.0 | 290 | |
| P61245 | 100.0 | 290 | |
| P68271 | 100.0 | 796 | |
| P68272 | 100.0 | 796 | |
| A1YG22 | 99.8 | 794 | |
| P23583 | 99.8 | 815 | |
| Q64210 | 99.1 | 819 | |
| P20389 | 99.1 | 819 | |
| B8XIA5 | 99.1 | 805 | |
| P01106 | 99.1 | 816 | |
Section 9: Transcription Factor Regulatory Data
MYC as Transcription Factor
MYC is a bHLH-ZIP transcription factor that forms heterodimers with MAX to regulate gene expression.
JASPAR DNA Binding Motifs (Total: 4)
| Motif ID | Name | Collection | Class | Family |
|---|
| MA0147.4 | MYC | CORE | Basic helix-loop-helix factors | bHLH-ZIP |
| MA0147.3 | MYC | CORE | Basic helix-loop-helix factors | bHLH-ZIP |
| MA0059.2 | MAX::MYC | CORE | Basic helix-loop-helix factors | bHLH-ZIP |
| MA0059.1 | MAX::MYC | CORE | Basic helix-loop-helix factors | bHLH-ZIP |
Downstream Targets (Genes Regulated BY MYC)
From SIGNOR database (Total: 172+ interactions)
Activated Targets (Top 30):
| Target Gene | Mechanism | Score |
|---|
| CCND1 | transcriptional regulation | 0.50 |
| CDK4 | transcriptional regulation | 0.57 |
| CDC25A | transcriptional regulation | 0.63 |
| CCNA2 | transcriptional regulation | 0.42 |
| CDK6 | transcriptional regulation | 0.45 |
| CUL1 | transcriptional regulation | 0.48 |
| DNMT3A | binding | 0.71 |
| LDHA | transcriptional regulation | 0.56 |
| HK2 | transcriptional regulation | 0.37 |
| SLC2A1 | transcriptional regulation | 0.43 |
| VEGFA | transcriptional regulation | 0.46 |
| ENO1 | transcriptional regulation | 0.41 |
| SIRT2 | transcriptional regulation | 0.47 |
Repressed Targets (Top 20):
| Target Gene | Mechanism | Score |
|---|
| CDKN1A | transcriptional regulation | 0.78 |
| CDKN2A | transcriptional regulation | 0.77 |
| CDKN2B | transcriptional regulation | 0.60 |
| CDKN1B | transcriptional regulation | 0.53 |
| SMAD2 | — | 0.68 |
| SMAD3 | binding | 0.69 |
| HLA-A | transcriptional regulation | 0.27 |
| HLA-B | transcriptional regulation | 0.27 |
| HLA-C | transcriptional regulation | 0.26 |
| DKK1 | transcriptional regulation | 0.39 |
| SFRP1 | transcriptional regulation | 0.36 |
Upstream Regulators (TFs that Regulate MYC)
From CollecTRI database (Total: 1,124+ regulatory relationships)
Activators of MYC:
| TF | Confidence |
|---|
| E2F1 | High |
| CTNNB1 (β-catenin) | High |
| CTCF | High |
| DLX5 | High |
| HNF4A | High |
| IKZF1 | High |
| NOTCH1 | (via SIGNOR) |
| STAT3 | (via SIGNOR) |
| LEF1 | High |
| FOXM1 | — |
| ERG | — |
Repressors of MYC:
| TF | Confidence |
|---|
| FOS | High |
| JUN | High |
| JUND | High |
| CEBPA | High |
| CEBPB | High |
| HOXB13 | High |
| IKZF3 | High |
| KLF11 | High |
| GLI1 | High |
| ENO1 | High |
| SMAD3/SMAD4 | (via SIGNOR) |
Section 10: Drug & Pharmacology Data
ChEMBL Targets (Total: 7)
| Target ID | Name | Type |
|---|
| CHEMBL1250348 | Myc proto-oncogene protein | SINGLE PROTEIN |
| CHEMBL3301395 | c-Myc/Max | PROTEIN COMPLEX |
| CHEMBL4106127 | c-Myc/c-Max | PROTEIN-PROTEIN INTERACTION |
| CHEMBL4296141 | VHL/Myc proto-oncogene protein | PROTEIN-PROTEIN INTERACTION |
| CHEMBL4888452 | MAP2K3/Myc proto-oncogene protein | PROTEIN-PROTEIN INTERACTION |
| CHEMBL5465202 | Cereblon/Myc proto-oncogene protein | PROTEIN-PROTEIN INTERACTION |
| CHEMBL5465553 | WDR5-MYC | PROTEIN-PROTEIN INTERACTION |
Targeting Molecules (from ChEMBL)
Total Molecules: 100+ compounds tested
Top Molecules by Development Phase:
| ChEMBL ID | Name | Type | Highest Phase |
|---|
| CHEMBL165 | RESVERATROL | Small molecule | Phase 3 |
| CHEMBL4297458 | EZOBRESIB | Small molecule | Phase 2 |
Note: MYC has historically been considered "undruggable" due to lack of deep binding pockets. Most compounds target MYC-MAX dimerization or upstream/downstream pathways.
PharmGKB
| Attribute | Value |
|---|
| PharmGKB ID | PA31353 |
| Symbol | MYC |
| VIP Gene | Yes |
| CPIC Guideline | No |
| Chromosome | chr8 |
Drug-Gene Interactions
MYC is annotated as a Very Important Pharmacogene (VIP) in PharmGKB, indicating clinical relevance in drug response.
Section 11: Expression Profiles
Bgee Expression Summary
| Attribute | Value |
|---|
| Gene ID | ENSG00000136997 |
| Species | Homo sapiens |
| Expression Breadth | Ubiquitous |
| Total Present Calls | 256 |
| Max Expression Score | 99.12 |
Tissue Expression (Top 50 tissues from Bgee via UBERON)
MYC is expressed ubiquitously across human tissues. Top tissues include:
| Tissue (UBERON) | ID |
|---|
| Spleen | UBERON:0002106 |
| Ovary | UBERON:0000992 |
| Lymph node | UBERON:0000029 |
| Mammary gland | UBERON:0001911 |
| Colon | UBERON:0001155 |
| Stomach | UBERON:0000945 |
| Small intestine | UBERON:0000160 |
| Pancreas | UBERON:0001264 |
| Uterus | UBERON:0000995 |
| Thyroid gland | — |
| Adrenal gland | UBERON:0002369 |
| Adipose tissue | UBERON:0001013 |
| Skin | UBERON:0000014 |
| Heart right ventricle | UBERON:0002080 |
| Lung (upper/lower lobes) | UBERON:0008948/0008949 |
| Esophagus | UBERON:0001043 |
| Liver | — |
| Tongue | UBERON:0001723 |
| Fallopian tube | UBERON:0003889 |
| Urinary bladder | UBERON:0001255 |
Single-Cell Expression Data (Total: 14 datasets)
| Experiment | Description | Cells |
|---|
| E-HCAD-29 | GM-CSF-producing T helper cells | 78,686 |
| E-MTAB-6701 | Fetal-maternal interface (10x) | 135,071 |
| E-MTAB-9841 | Mammary epithelial cells | 92,071 |
| E-HCAD-6 | CD34+ cells, bone marrow hematopoiesis | 34,596 |
| E-MTAB-10885 | Human milk cells vs non-lactating breast | 28,628 |
| E-MTAB-8205 | hPSC endothelial-to-haematopoietic transition | 25,764 |
| E-MTAB-8911 | Graft-Versus-Host Disease T-lymphocytes | 19,075 |
| E-MTAB-6524 | Human iPSCs | 10,926 |
| E-MTAB-8884 | Chronic myelomonocytic leukemia stem cells | 9,386 |
| E-MTAB-9067 | Foetal liver and bone marrow haematopoiesis | 5,865 |
| E-MTAB-8271 | Haemogenic endothelium in hPSC differentiation | 2,784 |
| E-CURD-6 | Human bone marrow, aneuploid cells | 1,024 |
| E-ENAD-20 | Xenograft, BRAF/MEK inhibitor treatment | 674 |
| E-GEOD-75688 | Primary breast cancer cells | 549 |
Section 12: Disease Associations
Orphanet Disease Associations (Total: 3)
| Orphanet ID | Disease Name | Type | Genes |
|---|
| 543 | Burkitt lymphoma | Disease | 1 |
| 480541 | High grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement | Disease | 3 |
| 99861 | Precursor T-cell acute lymphoblastic leukemia | Disease | 23 |
GenCC (Gene Curation Coalition)
| Gene | Disease | Classification |
|---|
| MYC | Burkitt lymphoma (OMIM:113970) | No Known Disease Relationship* |
Note: MYC translocations are a hallmark of Burkitt lymphoma; however, germline MYC mutations causing Mendelian disease have not been established.
HPO Phenotype Associations (Total: 18)
| HPO ID | Phenotype |
|---|
| HP:0030080 | Burkitt lymphoma |
| HP:0002733 | Abnormal lymph node morphology |
| HP:0005561 | Abnormal bone marrow cell morphology |
| HP:0002721 | Immunodeficiency |
| HP:0000137 | Abnormality of the ovary |
| HP:0001392 | Abnormality of the liver |
| HP:0001732 | Abnormality of the pancreas |
| HP:0001743 | Abnormality of the spleen |
| HP:0002017 | Nausea and vomiting |
| HP:0002027 | Abdominal pain |
| HP:0002149 | Hyperuricemia |
| HP:0002239 | Gastrointestinal hemorrhage |
| HP:0005214 | Intestinal obstruction |
| HP:0025435 | Increased circulating lactate dehydrogenase |
| HP:0032218 | Decreased CD4+ T cell proportion |
| HP:0100649 | Neoplasm of the oral cavity |
| HP:0001442 | Typified by somatic mosaicism |
| HP:0003745 | Sporadic |
GWAS Associations (Total: 51)
Top 30 GWAS Associations by Significance:
| Study ID | Trait | Mapped Gene(s) | P-value |
|---|
| GCST005933_10 | Non-glioblastoma glioma | CCDC26 | 2×10⁻⁶⁵ |
| GCST007856_84 | Colorectal cancer or advanced adenoma | PCAT1, CASC8, POU5F1B, CCAT2 | 3×10⁻⁶⁴ |
| GCST007856_6 | Colorectal cancer or advanced adenoma | POU5F1B, PCAT1, CASC8 | 2×10⁻⁵⁶ |
| GCST005931_16 | Glioma | CCDC26 | 1×10⁻³⁹ |
| GCST005933_9 | Non-glioblastoma glioma | CCDC26 | 8×10⁻³⁶ |
| GCST007800_55 | Asthma (childhood onset) | MYC - PVT1 | 1×10⁻²³ |
| GCST004093_26 | Prostate-specific antigen levels | PCAT1, CASC8, POU5F1B | 7×10⁻²¹ |
| GCST000842_5 | Bladder cancer | CASC11 | 2×10⁻¹⁸ |
| GCST002421_6 | Prostate cancer | CASC8 | 6×10⁻¹⁸ |
| GCST004166_56 | Nonsyndromic cleft lip with cleft palate | CCDC26 | 8×10⁻¹⁶ |
| GCST007010043_160 | Asthma | MYC - PVT1 | 3×10⁻¹⁵ |
| GCST002919_8 | Colorectal cancer | CASC8, PCAT1, POU5F1B | 6×10⁻¹⁵ |
| GCST005931_15 | Glioma | CCDC26 | 1×10⁻¹⁴ |
| GCST010042_34 | Asthma | MYC - PVT1 | 1×10⁻¹⁴ |
| GCST003017_15 | Colorectal cancer | PCAT1, CASC8, POU5F1B, CCAT2 | 4×10⁻¹⁴ |
| GCST004988_564 | Breast cancer | PVT1 | 1×10⁻¹³ |
| GCST006465_13 | Endometrial cancer (endometrioid) | LINC00824 - CCDC26 | 1×10⁻¹³ |
| GCST006464_13 | Endometrial cancer | LINC00824 - CCDC26 | 8×10⁻¹⁴ |
| GCST002411_9 | Colorectal cancer | PCAT1, CASC8, POU5F1B | 8×10⁻¹³ |
| GCST002636_5 | Diffuse large B cell lymphoma | PVT1 | 1×10⁻¹² |
Disease Categories with Strong GWAS Signal:
- Cancer: Colorectal, Bladder, Breast, Prostate, Ovarian, Pancreatic, Endometrial, Glioma, Lymphoma, Renal cell carcinoma
- Respiratory: Asthma, Allergic rhinitis, Allergic sensitization
- Developmental: Cleft lip/palate
- Other: Multiple sclerosis, Height
SUMMARY STATISTICS
| Category | Count |
|---|
| Gene Identifiers | 6 databases |
| Ensembl Transcripts | 15 |
| RefSeq Transcripts (human) | 2 |
| CCDS IDs | 2 |
| UniProt Accessions | 6 |
| InterPro Domains | 6 |
| Pfam Domains | 3 |
| PDB Structures | 25 |
| Vertebrate Orthologs | 4 species |
| ClinVar Variants | 46 |
| SpliceAI Predictions | 522 |
| AlphaMissense Predictions | 2,886 |
| Reactome Pathways | 19 |
| GO Annotations | 85 |
| STRING Interactions | 14,230+ |
| BioGRID Interactions | 5,810+ |
| TF Target Genes (SIGNOR) | 172+ |
| Upstream Regulators (CollecTRI) | 1,124+ |
| JASPAR Binding Motifs | 4 |
| ChEMBL Targets | 7 |
| GWAS Associations | 51 |
| HPO Phenotypes | 18 |
| Orphanet Diseases | 3 |
| Single-Cell Datasets | 14 |
Reference compiled from biobtree integrated database queries. Data current as of database version.
I have compiled a comprehensive cross-database identifier and functional mapping reference for human MYC covering all 12 requested sections. Key highlights:
Gene Summary:
MYC (HGNC:7553) encodes a bHLH-ZIP transcription factor at chromosome 8q24.21
Critical oncogene involved in cell cycle, proliferation, and apoptosis regulation
Forms heterodimers with MAX to regulate thousands of target genes
Key Counts:
15 Ensembl transcripts, 25 PDB structures, 6 UniProt entries
46 ClinVar variants (4 pathogenic), 522 SpliceAI predictions, 2,886 AlphaMissense predictions
14,230+ STRING interactions, 5,810+ BioGRID interactions
172+ downstream target genes, 1,124+ upstream regulatory relationships
51 GWAS associations linking to cancers (colorectal, bladder, breast, glioma, lymphoma) and other traits
Ubiquitous expression across 256 tissue/cell types
Clinical Relevance:
Hallmark translocation gene in Burkitt lymphoma
Associated with multiple cancer types via GWAS
Designated as a Very Important Pharmacogene (VIP)
Historically considered “undruggable” but Phase 2/3 compounds exist (Ezobresib, Resveratrol)